论文部分内容阅读
目的探讨肠道微生态制剂的药理作用与辅助治疗顽固性幽门螺杆菌(Hp)感染的临床疗效与安全性。方法选取2015年2月—2016年2月于玉山县下镇镇中心卫生院接受治疗的顽固性Hp感染患者90例,按照入院顺序将其分为对照组与研究组,各45例。对照组患者给予标准的四联疗法治疗(奥美拉唑+阿莫西林+甲硝唑+胶体果胶铋),研究组患者给予含肠道微生物制剂的四联疗法治疗(甲硝唑+奥美拉唑+阿莫西林+双歧杆菌三联活菌胶囊),比较两组患者的Hp根除率及不良反应发生情况。结果研究组患者Hp根除率为95.56%,对照组患者的Hp根除率为91.11%,两组患者Hp根除率比较,差异无统计学意义(P>0.05)。研究组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论含有肠道微生态制剂的四联疗法治疗顽固性Hp感染的临床疗效与标准四联疗法相当,但其不良反应少,安全性高。
Objective To investigate the pharmacological effects of intestinal probiotics and the clinical efficacy and safety of adjuvant therapy for refractory Helicobacter pylori (Hp) infection. Methods Totally 90 patients with refractory Hp infection were treated in Xiajian Town Center Hospital of Yushan County from February 2015 to February 2016. The patients were divided into control group and study group according to admission order, with 45 cases in each group. Patients in the control group were treated with standard quadruple therapy (omeprazole + amoxicillin + metronidazole + colloidal pectin gel), and patients in the study group were given quadruple therapy with metronomic microbes (metronidazole + Meprazole + amoxicillin + Bifidobacterium triple viable capsule), Hp eradication rate and adverse reactions in two groups were compared. Results The Hp eradication rate was 95.56% in the study group and 91.11% in the control group. There was no significant difference between the two groups in the Hp eradication rate (P> 0.05). The incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of quadruple therapy with enteric probiotics in the treatment of refractory Hp infection is comparable to standard quadruple therapy but with less adverse reactions and higher safety.